A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias
DW Kim, P Le Coutre, R Paquette… - … England Journal of …, 2013 - Mass Medical Soc
Background Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated
BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor–refractory threonine-to …
BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor–refractory threonine-to …
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
JE Cortes, DW Kim, J Pinilla-Ibarz… - The New England …, 2013 - europepmc.org
Background Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated
BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine-to …
BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine-to …
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias
JE Cortes, DW Kim, J Pinilla-Ibarz… - New England …, 2013 - augusta.elsevierpure.com
BACKGROUND: Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and
mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine …
mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine …
[PDF][PDF] A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias
J DiPersio - 2013 - digitalcommons.wustl.edu
Background Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated
BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor–refractory threonineto …
BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor–refractory threonineto …
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias
JE Cortes, DW Kim, J Pinilla-Ibarz, P Le Coutre… - 2013 - scholarbank.nus.edu.sg
BACKGROUND: Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and
mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine …
mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine …
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias
JE Cortes, DW Kim, J Pinilla-Ibarz, P Le Coutre… - 2013 - hekyll.services.adelaide.edu.au
Background: Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated
BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonineto …
BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonineto …
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias
J Cortes, D Kim, J Pinilla Ibarz, P le Coutre… - NEW ENGLAND …, 2013 - boa.unimib.it
Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL,
including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine-to-isoleucine …
including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine-to-isoleucine …
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias
JE Cortes, DW Kim, J Pinilla-Ibarz, P Le Coutre… - 2013 - digital.library.adelaide.edu.au
Background: Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated
BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonineto …
BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonineto …
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias
JE Cortes, DW Kim… - New England …, 2013 - mdanderson.elsevierpure.com
BACKGROUND: Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and
mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine …
mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine …
[HTML][HTML] A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
JE Cortes, DW Kim, J Pinilla-Ibarz… - The New England …, 2013 - ncbi.nlm.nih.gov
BACKGROUND Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and
mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor–refractory …
mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor–refractory …